Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
To be honest I hope it stay at these levels until Wednesday, funds clearing then to make my final purchase! Amazes me to see the shortsightedness of some people. Oh well, as you sow, so shall you reap!
Punit's confidence of something big in our hands is very obvious. GLTA!
No worries. Yes, the exposure is building up. Up 10% today!!
Is it different from the seeking alpha interview? Can you post the link?
Btw new analyst coverage today with $8 price target.
http://www.analystratings.net/stocks/NASDAQ/RXII/
Really appreciate your effort, Dr. Bob! Thanks!
Looking forward to this week!
Makes more sense actually.
You as well!
Lol, you never know.
Excellent comment zoriden on an excellent news source.
Immune Therapy’s Cancer Promise Creates Research Rush
From Punit's Twitter.
A good PR in the morning could spike the price up even before the event starts. So congrats to the longs and if you are new, a little bit of a higher price wouldn't be that bad IMO. Immunotherapy has a big potential and so do we.
Systemic response will be the holy grail of cancer treatment and we're leading the way. Glad to be an investor in this wonderful company.
OncoSec Medical to present at four events in June
http://www.marketwatch.com/story/oncosec-medical-to-present-at-four-events-in-june-2014-05-27?reflink=MW_news_stmp
Even if a partnership is guaranteed to happen, IMO it cannot be priced in yet since the market doesn't know the terms and conditions of the partnership (pps doesn't react to partnerships in a binary fashion and depends on the conditions set forth IMO).
I doubt we will need a R/S if we see a similar run up as INO's. The CEO has constantly reiterated organic uplisting and I think with the trials we have going on in Phase 2, if the results are positive we will not need to go the R/S path.
To each his own DD.
Haha will be fun to watch his facial expressions if the reporter grills him on the partner.
The history (and significance) of the Marcum Conference
"Last year’s conference featured presentations by senior executives from 120 microcap companies and was attended by 1600 institutional investors, buy- and sell-side analysts, investment bankers and service providers to the microcap market. In addition to corporate presentations, private one-on-one meetings between companies and investors are facilitated throughout the day, and expert panels on timely topics relevant to the microcap community are also offered"- See more at: http://marcumllp.com/microcap/history#sthash.iA5CHisX.dpuf
No biggie but tweet from Punit this morning in response to "any update from the events this month, how's everything been?"
-> "Definitely a busy month. We're looking forward to Marcum and ASCO."
Can't wait!
Hoping there's no major move until ASCO. Buying one final lot next week! Happy Memorial Day weekend to all!
Couldn't agree more money.
With good ph2 update $6 at least since it got there for no apparent reason some time back?
Have been a long since the low .20s and added a couple of times on the way up. Thanks to posters on this board whose DD is simply amazing. GLTA!
Indeed! Everyone have a great weekend!
Funny story, I typed Oncosec on Google to see if there was any news today and Google's auto-complete suggested "Oncosec Medical Merck"
Bristol, Merck, Roche immune therapies are cancer darlings
By Bill Berkrot
(Reuters) - When the world's leading cancer doctors meet in Chicago next month, new treatments from Merck & Co, Bristol-Myers Squibb Co and Roche Holding AG that help the immune system fight disease are expected to capture much of the spotlight.
The drugs, known as anti-PD-1 or anti-PDL1 therapies, are biotech medicines that work by blocking a tumor's ability to camouflage itself, thereby allowing T cells in the immune system to recognize and attack the cancer.
They have shown great promise against advanced melanoma - the deadliest of skin cancers - as well as advanced lung and kidney cancers, with relatively mild side effects, generating excitement among researchers and investors.
At the American Society of Clinical Oncology meeting in Chicago beginning May 30, researchers will for the first time present data on Roche's anti-PDL1 drug in advanced bladder cancer for which there have been few advances in decades.
Merck will have no less than 16 studies involving its highly touted anti PD-1 drug, MK-3475, including a first look at the drug as an initial lung cancer treatment. Early data released on Wednesday showed 36 percent of 45 patients had an initial immune response to the treatment. Merck will also provide results from the first trial of the drug in head and neck cancer.
Brief summaries, or abstracts, of thousands of studies to be presented at the ASCO meeting were released on Wednesday.
"This area should represent a major advance in cancer therapy and patient survivability," said Len Yaffe, portfolio manager for the healthcare fund StockDoc Partners. "Wall Street is increasingly recognizing the multibillion-dollar potential for cancer immunotherapies."
The potential for lasting effects of these drugs will be on display in a pair of studies involving the Bristol-Myers anti PD-1 drug nivolumab.
Researchers will present follow-up data from a 107-patient nivolumab study in metastatic melanoma showing that 41 percent were still alive after three years, an apparent leveling off from the 48 percent survival rate after two years.
Three-year survival with advanced melanoma was virtually unheard of prior to the advent of cancer immunotherapy.
In a trial of patients whose advanced kidney cancer had progressed following prior treatments, the mean overall survival was 25.5 months for the 2 milligram nivolumab dose.
Past kidney cancer studies of drugs currently in use have demonstrated a mean survival of about 14 months, said Fouad Namouni, Bristol's head of global development for nivolumab.
MOST LIKELY TO BENEFIT
As drugmakers face greater scrutiny over how they price new therapies - with immuno-oncology expected to be among the most expensive - several studies will aim to identify which patients are most likely to benefit from the new treatments.
Researchers can now perform a test to determine the degree to which the PD-L1 protein is expressed on the surface of cancer cells. On a 0 to 3 scale, a score of 0 or 1 is considered PD-L1 negative, while 2 or 3 is deemed PD-L1 positive.
If early data is confirmed in larger trials, this class of immunotherapies could become standalone treatments for some patients, while PD-L1 negative patients may require combination or alternative therapies, according to some researchers.
In a small, Phase I study of Bristol's nivolumab in previously untreated patients with advanced lung cancer, five out of 10 PD-L1 positive patients saw their tumors shrink by at least 30 percent. No such responses were seen among 7 PD-L1 negative patients. Roche also saw half of the 20 PD-L1 positive patients in its bladder cancer trial respond to its drug.
Namouni said Bristol would focus on PD-L1 positive patients only in a large Phase III lung cancer trial of previously untreated subjects. Its Phase III studies of those who had received prior treatments will include PD-L1 negative patients.
(Reporting by Bill Berkrot; Editing by Michele Gershberg and Andre Grenon)
We are so getting partnered or bought out. The question is, who will have the best offer. Exciting times to be an OncoSec shareholder.
Immunotherapy Drugs Show Promise Treating a Range of Cancers
"Bristol-Myers Squibb Co., Merck & Co., Roche Holding AG and other companies are racing to bring new immunotherapy drugs to what analysts predict will be a multibillion-dollar market. So far, these drugs have shown the most promise in melanoma, a deadly skin cancer, and in lung cancer."
http://m.us.wsj.com/articles/SB10001424052702304547704579562052553432802?mg=reno64-wsj
Yes, I'd rather they release a PR on the day of the conference. I think that will create a bigger bang than releasing one now. In the mean time, great opportunity for DD longs to add more while it is this cheap.
Yup, and inveterate, you should also try joining the StockTwits RXII board. There's a nice following there with more activity and many of the posters from this board also post on it regularly.
Good one ero lol.
Sounds very likely. GLTA!
Moneypenny, Erostratus, Jbem, Zoriden, and others, it is a privilege to have people like you on this board. I've learned so much about what true due diligence really means. Thank you all and best of luck to us all! Exciting times ahead! $ONCS.
Great observation jbem. You could be right in that Merck could in fact be crossing their T's and dotting their I's with this. We shall find out soon. GLTA.
ARVO Extract (See page 2):
http://www.arvo.org/webs/am2014/abstract/sessions/534.pdf
Thanks MoneyInc365 for sharing.
New article: Taking a Look at RXI Pharmaceuticals Before Hypertonic Scar Phase 2 Results
http://www.biotechpicklist.com/taking-a-look-at-rxi-pharmaceuticals-before-hypertrophic-scar-phase-2-results/
Have been in with a modest position for some time. This year is looking good. Do you think there is a possibility to uplist to NASDAQ organically this year?
New Article: RXi Pharma's Anti-Scarring Drug Shows Potential In Study
http://www.clinicalleader.com/doc/rxi-pharma-s-anti-scarring-drug-shows-potential-in-study-0001
Thanks to KosherFrank from StockTwits for sharing the link.
Lol, I meant for May overall.
Fasten your seatbelts folks.